Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.43 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA3 | P07451 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | MB | P02144 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341653 | 0.89 | HPGD (0.46) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL14367054 | 0.82 | L3MBTL1 (0.41) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL7518002 | 0.80 | MAPT (0.50) | ALDH1A1MAPTKMT2ALMNAHPGD | |
| SCHEMBL1157660 | 0.78 | MAPT (0.55) | CA2CA1ALDH1A1MAPTBRD4 | |
| SCHEMBL9799523 | 0.78 | MAPT (0.55) | CA2CA1ALDH1A1MAPTBRD4 | |
| SCHEMBL4232728 | 0.78 | TPMT (0.41) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL15694511 | 0.78 | CES2 (0.42) | CA2CA1ALDH1A1MAPTMEN1 | |
| SCHEMBL28066049 | 0.78 | TSHR (0.46) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL6038269 | 0.78 | HPGD (0.38) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL27311837 | 0.78 | HPGD (0.67) | ALDH1A1MAPTKMT2AHSD17B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0302321-A2 | Process for the preparation of thiophenols, and these thiophenols | BAYER AG (DE) | 1989-02-08 | — | — | EP | claimed |
| CN-101302177-B | Phenolic compound and recording material containing the same | NIPPON SODA CO | 2013-01-23 | — | — | CN | disclosed |
| CN-100451001-C | Phenolic compound and recording material using the same | NIPPON SODA CO (JP) | 2009-01-14 | — | — | CN | disclosed |
| CN-101302177-A | Phenolic compound and recording material containing the same | NIPPON SODA CO (JP) | 2008-11-12 | — | — | CN | disclosed |
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ASTAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| CN-1639116-A | Phenolic compound and recording material using the same | NIPPON SODA CO (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-1539740-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024715-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| EP-0302321-A2 | Process for the preparation of thiophenols, and these thiophenols | BAYER AG (DE) | 1989-02-08 | — | — | EP | disclosed |
| US-4025399-A | ELECTRICAL, RECORDING LAYER WITH A CONDUCTIVE AGENT, A LEUCO BASE AND A PHENOLIC RESIN | CANON KABUSHIKI KAISHA (JA) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ADAM10, ADAM17, TNF | NR1H2 1272/4885CA2 1011/4885CA1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.